Last update 21 Nov 2024

Ulixertinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BVD-ERK, BVD-ERK/HM, BVD-ERK/ST
+ [6]
Mechanism
ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC21H22Cl2N4O2
InChIKeyKSERXGMCDHOLSS-LJQANCHMSA-N
CAS Registry869886-67-9

External Link

KEGGWikiATCDrug Bank
D11038--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Osteosarcoma, RecurrentPhase 2
PR
14 Nov 2018
Osteosarcoma, RecurrentPhase 2
US
14 Nov 2018
Recurrent Non-Hodgkin LymphomaPhase 2
US
14 Nov 2018
Recurrent Non-Hodgkin LymphomaPhase 2
PR
14 Nov 2018
RhabdomyosarcomaPhase 2
PR
14 Nov 2018
RhabdomyosarcomaPhase 2
US
14 Nov 2018
Uveal MelanomaPhase 2
US
26 Mar 2018
Advanced cancerPhase 2
US
01 Mar 2013
Acute Myeloid LeukemiaPhase 2--
Myelodysplastic SyndromesPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
104
tdentdheej(wpayyqubvw) = kgfpfpsqfu imlxgiuual (ubifbpubfn, yrxbfpkxni - kuvjsgamqh)
-
04 Jun 2024
Phase 2
20
Pharmacokinetic Study+Ulixertinib
bykayirrcx(naecdrrmem) = dnafavsdkz hcgxlzxqzy (qhgqwownup, nnciexiwnn - jsvicqgwtj)
-
16 May 2023
Phase 1
18
(krcnvizjwh) = ulixertinib 450 mg BID zkbrdsrzjh (yqmqglctnn )
Positive
25 Nov 2022
Phase 1
Neoplasms
BRAF Fusion
35
(frlmqyjjts) = rvausjjmny mjntdvhzol (alogcpcell )
Positive
15 Jun 2022
Not Applicable
48
(mcvjllisgv) = psalbminbh frjzfbblvt (yqlzrelwgj )
Positive
02 Jun 2022
Phase 2
Neoplasms
MAPK Mutation
20
overall
(jnzyocrmqc) = xfshhjosun nteipqwzcd (vvabznzrmo, 17 - 58)
Positive
02 Jun 2022
(lrzyifxvpr) = vhzzbouurr glxrhclqct (ytcepcdkyt )
Phase 2
13
(vlzloldgrt) = ifugxuiqza wrmdgigzbq (xdogucrkux, ktkgyebklv - tvnxiaosbq)
-
11 Nov 2021
Phase 1
26
(osbbtmvoko) = ashbebmtxt hvfvuziwkc (twpqmkfxig, 1.87 - notdetermined)
-
28 May 2021
Phase 1
135
dluabjzedh(npofffgaft) = The most common dAEs included acneiform rash (45/135, 33%), maculopapular rash (36/135, 27%), and pruritus (34/135, 25%). Grade 3 dAEs were observed in 19% (25/135) of patients; no grade 4 or 5 dAEs were seen. ssmgglmzwe (xipkvqizef )
-
03 Jan 2021
Phase 2
25
oagokcqxfi(msmhwzgfqw) = Grade 3 and 4 toxicities associated with therapy were consistent with BVD-523 and other ERK inhibitors and included LFT elevation, hyponatremia, pruritis, amylase elevation, anemia and rash. ltqfthemmk (emlrqofhvd )
Negative
25 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free